These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 21502403)

  • 21. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
    Kewitz S; Bernig T; Staege MS
    Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
    Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
    Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
    Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
    Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.
    Kuratnik A; Senapati VE; Verma R; Mellone BG; Vella AT; Giardina C
    Biochem Pharmacol; 2012 May; 83(9):1217-28. PubMed ID: 22306067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
    Paller CJ; Wissing MD; Mendonca J; Sharma A; Kim E; Kim HS; Kortenhorst MS; Gerber S; Rosen M; Shaikh F; Zahurak ML; Rudek MA; Hammers H; Rudin CM; Carducci MA; Kachhap SK
    Cancer Med; 2014 Oct; 3(5):1322-35. PubMed ID: 24989836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
    Chun SG; Zhou W; Yee NS
    Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
    Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
    World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
    Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
    Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
    He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
    Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
    Di Gennaro E; Bruzzese F; Pepe S; Leone A; Delrio P; Subbarayan PR; Avallone A; Budillon A
    Cancer Biol Ther; 2009 May; 8(9):782-91. PubMed ID: 19270508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
    Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
    Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
    Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS; Cranmer LD
    BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
    Pan CH; Chang YF; Lee MS; Wen BC; Ko JC; Liang SK; Liang MC
    BMC Cancer; 2016 Nov; 16(1):857. PubMed ID: 27821078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase.
    Yang D; Liu H; Goga A; Kim S; Yuneva M; Bishop JM
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13836-41. PubMed ID: 20643922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
    Lindemann RK; Newbold A; Whitecross KF; Cluse LA; Frew AJ; Ellis L; Williams S; Wiegmans AP; Dear AE; Scott CL; Pellegrini M; Wei A; Richon VM; Marks PA; Lowe SW; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2007 May; 104(19):8071-6. PubMed ID: 17470784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.